17-allylamino-17-demethoxygeldanamycin
GPTKB entity
Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antineoplastic agent |
| gptkbp:abbreviation |
gptkb:17-AAG
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:CASNumber |
75747-14-7
|
| gptkbp:category |
antitumor antibiotic
|
| gptkbp:chemicalFormula |
C31H43N3O8
|
| gptkbp:derivedFrom |
gptkb:geldanamycin
|
| gptkbp:developedBy |
antineoplastic agent
|
| https://www.w3.org/2000/01/rdf-schema#label |
17-allylamino-17-demethoxygeldanamycin
|
| gptkbp:mechanismOfAction |
Hsp90 inhibitor
|
| gptkbp:molecularWeight |
587.7 g/mol
|
| gptkbp:synonym |
tanespimycin
|
| gptkbp:target |
gptkb:heat_shock_protein_90
|
| gptkbp:used_in |
clinical trials
|
| gptkbp:bfsParent |
gptkb:17-AAG
|
| gptkbp:bfsLayer |
8
|